GlassScriptPhysician profile
Christopher Alan Wood
NPI 1609837970
$4,915.81
in general payments reported to CMS, 2019-2025
46 companies · $979 in 2025
The $979 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $728 · 2020: $558 · 2021: $781 · 2022: $625 · 2023: $558 · 2024: $687 · 2025: $979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,179 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,179.22 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $715.52 | 2019-2025 | Vraylar, Qulipta |
| Pfizer INC. | $627.04 | 2019-2025 | |
| Lilly USA, LLC | $515.24 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $451.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $279.40 | 2019-2025 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $212.53 | 2019-2025 | Airsupra, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $199.61 | 2019-2022 | |
| Amgen INC. | $194.47 | 2019-2025 | Otezla, Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $179.04 | 2020-2023 | Spravato |
| Amarin Pharma, INC. | $178.24 | 2019-2021 | |
| Lundbeck LLC | $97.45 | 2022-2025 | Vyepti, Rexulti |
| Astellas Pharma US INC | $90.17 | 2021-2025 | Veozah |
| Merck Sharp & Dohme LLC | $80.96 | 2019-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Horizon Therapeutics Plc | $80.75 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.92 | 2020-2025 | Xifaxan, Trulance |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Wood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.